#SFHS2608514AOrder of April 8, 2026 amending the list of reimbursable pharmaceutical specialties for social insurance beneficiaries
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This law expands the reimbursement list for certain medications used to treat rare lung diseases in children and adolescents aged 6 to 17 in France. It includes specific treatments for interstitial lung diseases and conditions linked to systemic sclerosis, making these medications more accessible through health insurance coverage.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Additional medications are now reimbursable for rare lung diseases in children aged 6 to 17.
- Coverage includes treatments for interstitial lung diseases and systemic sclerosis.
- OFEV capsules in specific dosages have been added to the reimbursable list.
Obligations
What this law requires
Add OFEV 25 mg (nintédanib) capsules in presentations of 120 and 180 capsules (CIP codes 34009303089 3 6 and 34009303089 4 3) to the list of reimbursable pharmaceutical specialties for social insurance beneficiaries
Restrict reimbursement of newly added OFEV 25 mg to treatment of fibrosing, progressive, and clinically significant diffuse interstitial lung disease (PID) in children and adolescents aged 6 to 17 years
Extend reimbursement coverage of OFEV 100 mg (nintédanib) capsules in 60-capsule presentation (CIP code 34009300060 2 3) to treatment of fibrosing, progressive, and clinically significant diffuse interstitial lung disease (PID) in children and adolescents aged 6 to 17 years
Extend reimbursement coverage of OFEV 150 mg (nintédanib) capsules in 60-capsule presentation (CIP code 34009300060 4 7) to treatment of fibrosing, progressive, and clinically significant diffuse interstitial lung disease (PID) in children and adolescents aged 6 to 17 years
Extend reimbursement of OFEV 100 mg and 150 mg to treatment of diffuse interstitial lung disease associated with systemic sclerosis (PID-ScS) in children and adolescents aged 6 years and older